Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL Proceeds from long-term liabilities and other

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%
Enterprise value$1.88B+100.0%
P/S23.3×-26.8×

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Reported directly by AbCellera Biologics Inc. in its filing.

Tagged under the XBRL concept abcl:ProceedsFromLongTermLiabilitiesAndStockOptionsExercised.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s proceeds from long-term liabilities and other.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s proceeds from long-term liabilities and other?
AbCellera Biologics Inc. (ABCL) reported proceeds from long-term liabilities and other of $7.19M in Q1 2026.
How has AbCellera Biologics Inc.'s proceeds from long-term liabilities and other changed year-over-year?
AbCellera Biologics Inc.'s proceeds from long-term liabilities and other increased by 20.5% year-over-year, from $5.97M to $7.19M.